The BCS: Where Do We Go From Here?

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-07-02-2001
Volume 25
Issue 7

The Biopharmaceutics Classification System, which is used to regulate the bioequivalence of oral drug products, may become an essential tool in future drug development efforts.

External Link - article-5540.pdf

Articles in this issue
Musings on the Past 25 Years
Reflections on Changes at FDA
Deliver the Dose
Middle-European Pharmaceutics in a Changing World
The BCS: Where Do We Go From Here?
The Role of USP in the Assessment of Microbiological Quality of Pharmaceuticals
From Inactive Ingredients to Pharmaceutical Excipients
Am I Going Backwards?
The Filter Scene: Old and New
Catching Up with Expert Systems
25 Years of Change in the Parenteral Technology Field
The Future State of Computer Validation, Part I
Statistical Thinking
2001: An Odyssey in Inhaler Formulation and Design
What Is the "Correct" Method to Use for Particle-Size Determination?
Recent Videos
Training Centers and eCommerce: A Look Into Federal Equipment Company’s Pharma Innovations
Training Centers and eCommerce: A Look Into Federal Equipment Company’s Pharma Innovations
Behind the Headlines, Episode 18
Behind the Headlines, Episode 18: Sanofi, GSK Go Big in M&A, mRNA Momentum Falters, and More
From Discovery to Delivery: How Piramal Pharma Limited is Strengthening its Drug Development Capabilities
From Discovery to Delivery: How Piramal Pharma Limited is Strengthening its Drug Development Capabilities
A CDMO’s Role in API Quality
A CDMO’s Role in API Quality
CPHI Americas 2025: The Evolving Role of the CDMO
CPHI Americas 2025: The Evolving Role of the CDMO
Inside Experic: Revolutionizing CDMO & Clinical Packaging Services
Inside Experic: Revolutionizing CDMO & Clinical Packaging Services
Drug Digest: Patient Preference Drives Solid Dosage Trends
Drug Digest: Patient Preference Drives Solid Dosage Trends
Ask the Expert: Quality Control Units
Ask the Expert: Quality Control Units
Behind the Headlines, Episode 17
Behind the Headlines, Episode 17: Bespoke CRISPR Therapy, Executive Order Fallout, and More
Industry Outlook 2025: European Political Impacts on the Supply Chain
Industry Outlook 2025: European Political Impacts on the Supply Chain
Related Content
mainz,Rhineland-Palatinate /germany - 16 07 2022: the biontech company building and flags in mainz germany | Image Credit: © Tobias Arhelger - stock.adobe.com

CureVac to Be Acquired by BioNTech in $1.25B Deal to Advance mRNA Cancer Therapies

Christopher Cole
June 12th 2025
Article

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer immunotherapies.

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Patrick Lavery
May 30th 2025
Podcast

In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.

Darmstadt, Germany - November 10, 2021: A building at the headquarters of science and technology company Merck KGaA. | Image Credit: © Anne Czichos - stock.adobe.com

MilliporeSigma and Simtra Launch Five-Year Agreement for Drug Substance, Drug Manufacturing Services

Patrick Lavery
June 11th 2025
Article

The agreement has been designed to offer a turnkey service to companies seeking faster time to market.

Site Logo

Transformations in Drug Development for Cell and Gene Therapies

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

Logo of Merck KgA, Merck is a German multinational science and technology company. | Image Credit: © Robert - stock.adobe.com

China’s NMPA Approves Merck KGaA Treatment for Tenosynovial Giant Cell Tumor

Patrick Lavery
June 10th 2025
Article

NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with TGCTs that require systemic treatment.

Abstract vertical illustration of targeting cancer cell made of glowing neon particles. Blue geometric background depicting cancer cell screening and disease treatment medical concept. Digital art | Image Credit: © artacet - stock.adobe.com

Advancements in Biopharma Spur Innovation

Susan Haigney
June 10th 2025
Article

The quickly evolving development of biopharmaceuticals is impacting innovation in the industry overall.